Allegiance Financial Group Advisory Services LLC Purchases Shares of 8,710 Pfizer Inc. (NYSE:PFE)

Allegiance Financial Group Advisory Services LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 8,710 shares of the biopharmaceutical company’s stock, valued at approximately $231,000.

A number of other large investors also recently bought and sold shares of PFE. Swedbank AB increased its position in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares in the last quarter. Pallas Capital Advisors LLC boosted its stake in Pfizer by 54.8% during the third quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock worth $736,000 after buying an additional 9,102 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Pfizer by 132.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,361 shares of the biopharmaceutical company’s stock worth $589,000 after buying an additional 11,615 shares during the last quarter. Integrated Advisors Network LLC boosted its stake in Pfizer by 18.3% during the third quarter. Integrated Advisors Network LLC now owns 64,014 shares of the biopharmaceutical company’s stock worth $1,853,000 after buying an additional 9,925 shares during the last quarter. Finally, Fidelis Capital Partners LLC boosted its stake in Pfizer by 5.2% during the third quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock worth $746,000 after buying an additional 1,267 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 1.3 %

NYSE:PFE opened at $26.40 on Thursday. The stock’s 50 day moving average price is $26.34 and its 200 day moving average price is $27.36. The company has a market capitalization of $149.63 billion, a PE ratio of 18.73, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.51%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Guggenheim reissued a “buy” rating and set a $33.00 target price on shares of Pfizer in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average price target of $31.92.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.